TY - JOUR
T1 - Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessive-compulsive disorder
AU - Denys, Damiaan
AU - Mantione, Mariska
AU - Figee, Martijn
AU - Van Den Munckhof, Pepijn
AU - Koerselman, Frank
AU - Westenberg, Herman
AU - Bosch, Andries
AU - Schuurman, Rick
PY - 2010/10
Y1 - 2010/10
N2 - Context: Obsessive-compulsive disorder (OCD) is a chronic psychiatric disorder that affects 2% of the general population. Even when the best available treatments are applied, approximately 10% of patients remain severely afflicted and run a long-term deteriorating course of OCD. Objective: To determine whether bilateral deep brain stimulation of the nucleus accumbens is an effective and safe treatment for treatment-refractory OCD. Design: The study consisted of an open 8-month treatment phase, followed by a double-blind crossover phase with randomly assigned 2-week periods of active or sham stimulation, ending with an open 12-month maintenance phase. Setting: Academic research. Patients: Sixteen patients (age range, 18-65 years) with OCD according to DSM-IV criteria meeting stringent criteria for refractoriness to treatment were included in the study. Interventions: Treatment with bilateral deep brain stimulation of the nucleus accumbens. Main Outcome Measures: Primary efficacy was assessed by score change from baseline on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Responders were defined by a score decrease of at least 35% on the Y-BOCS. Results: In the open phase, the mean (SD) Y-BOCS score decreased by 46%, from 33.7 (3.6) at baseline to 18.0 (11.4) after 8 months (P<.001). Nine of 16 patients were responders, with amean (SD) Y-BOCS score decrease of 23.7 (7.0), or 72%. In the double-blind, sham-controlled phase (n=14), the mean (SD) Y-BOCS score difference between active and sham stimulation was 8.3 (2.3), or 25% (P=.004). Depression and anxiety decreased significantly. Except for mild forgetfulness and word-finding problems, no permanent adverse events were reported. Conclusion: Bilateral deep brain stimulation of the nucleus accumbens may be an effective and safe treatment for treatment-refractory OCD. Clinical Trial Registration: isrctn.org Identifier: ISRCTN23255677
AB - Context: Obsessive-compulsive disorder (OCD) is a chronic psychiatric disorder that affects 2% of the general population. Even when the best available treatments are applied, approximately 10% of patients remain severely afflicted and run a long-term deteriorating course of OCD. Objective: To determine whether bilateral deep brain stimulation of the nucleus accumbens is an effective and safe treatment for treatment-refractory OCD. Design: The study consisted of an open 8-month treatment phase, followed by a double-blind crossover phase with randomly assigned 2-week periods of active or sham stimulation, ending with an open 12-month maintenance phase. Setting: Academic research. Patients: Sixteen patients (age range, 18-65 years) with OCD according to DSM-IV criteria meeting stringent criteria for refractoriness to treatment were included in the study. Interventions: Treatment with bilateral deep brain stimulation of the nucleus accumbens. Main Outcome Measures: Primary efficacy was assessed by score change from baseline on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Responders were defined by a score decrease of at least 35% on the Y-BOCS. Results: In the open phase, the mean (SD) Y-BOCS score decreased by 46%, from 33.7 (3.6) at baseline to 18.0 (11.4) after 8 months (P<.001). Nine of 16 patients were responders, with amean (SD) Y-BOCS score decrease of 23.7 (7.0), or 72%. In the double-blind, sham-controlled phase (n=14), the mean (SD) Y-BOCS score difference between active and sham stimulation was 8.3 (2.3), or 25% (P=.004). Depression and anxiety decreased significantly. Except for mild forgetfulness and word-finding problems, no permanent adverse events were reported. Conclusion: Bilateral deep brain stimulation of the nucleus accumbens may be an effective and safe treatment for treatment-refractory OCD. Clinical Trial Registration: isrctn.org Identifier: ISRCTN23255677
UR - http://www.scopus.com/inward/record.url?scp=77957707659&partnerID=8YFLogxK
U2 - 10.1001/archgenpsychiatry.2010.122
DO - 10.1001/archgenpsychiatry.2010.122
M3 - Article
C2 - 20921122
AN - SCOPUS:77957707659
SN - 0003-990X
VL - 67
SP - 1061
EP - 1068
JO - Archives of General Psychiatry
JF - Archives of General Psychiatry
IS - 10
ER -